JP2022538778A5 - - Google Patents

Info

Publication number
JP2022538778A5
JP2022538778A5 JP2021573759A JP2021573759A JP2022538778A5 JP 2022538778 A5 JP2022538778 A5 JP 2022538778A5 JP 2021573759 A JP2021573759 A JP 2021573759A JP 2021573759 A JP2021573759 A JP 2021573759A JP 2022538778 A5 JP2022538778 A5 JP 2022538778A5
Authority
JP
Japan
Application number
JP2021573759A
Other languages
Japanese (ja)
Other versions
JP2022538778A (ja
JP7742311B2 (ja
JPWO2020252472A5 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037783 external-priority patent/WO2020252472A2/en
Publication of JP2022538778A publication Critical patent/JP2022538778A/ja
Publication of JP2022538778A5 publication Critical patent/JP2022538778A5/ja
Publication of JPWO2020252472A5 publication Critical patent/JPWO2020252472A5/ja
Application granted granted Critical
Publication of JP7742311B2 publication Critical patent/JP7742311B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021573759A 2019-06-14 2020-06-15 Muc1に対する抗体およびその使用方法 Active JP7742311B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861619P 2019-06-14 2019-06-14
US62/861,619 2019-06-14
PCT/US2020/037783 WO2020252472A2 (en) 2019-06-14 2020-06-15 Antibodies against muc1 and methods of use thereof

Publications (4)

Publication Number Publication Date
JP2022538778A JP2022538778A (ja) 2022-09-06
JP2022538778A5 true JP2022538778A5 (https=) 2023-02-10
JPWO2020252472A5 JPWO2020252472A5 (https=) 2023-02-10
JP7742311B2 JP7742311B2 (ja) 2025-09-19

Family

ID=73782134

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573759A Active JP7742311B2 (ja) 2019-06-14 2020-06-15 Muc1に対する抗体およびその使用方法

Country Status (6)

Country Link
US (1) US12448462B2 (https=)
EP (1) EP3983447A4 (https=)
JP (1) JP7742311B2 (https=)
AU (2) AU2020290579B2 (https=)
CA (1) CA3141926A1 (https=)
WO (1) WO2020252472A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3162246A1 (en) * 2019-12-20 2021-06-24 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
JP2024534148A (ja) * 2021-08-27 2024-09-18 ペプトロン インコーポレイテッド 新規抗muc1抗体およびその用途
KR20250156802A (ko) * 2023-03-03 2025-11-03 비원 메디슨즈 아이 게엠베하 Muc1 및 cd16a 항체 및 사용 방법
EP4676976A1 (en) * 2023-03-03 2026-01-14 Beone Medicines I GmbH Muc1 antibodies and methods of use
AU2024318998A1 (en) * 2023-07-31 2026-01-22 Sun Pharma Advanced Research Company Limited Humanized muc1 antibody and antibody drug conjugate

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
JPH0494693A (ja) 1990-08-08 1992-03-26 Nippon Mektron Ltd アフィジコリンの製造法
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1815021A2 (en) 2004-11-03 2007-08-08 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
AU2006321553B2 (en) 2005-12-08 2012-03-08 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
US8962806B2 (en) 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
WO2013026015A1 (en) 2011-08-18 2013-02-21 Dana-Farber Cancer Institute, Inc. Muc1 ligand traps for use in treating cancers
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
PT2961831T (pt) 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
US10059775B2 (en) * 2014-01-29 2018-08-28 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
JP6795505B2 (ja) 2014-10-06 2020-12-02 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド ヒト化ccケモカイン受容体4(ccr4)抗体およびその使用法
EP3227324A4 (en) * 2014-12-05 2018-08-29 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
BR112017013176A2 (en) 2014-12-19 2018-05-15 Dana-Farber Cancer Institute Inc. chimeric antigen receptors and methods for using them
EP3288977B1 (en) 2015-05-01 2021-11-17 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression with anti ccr4 antibodies
US10617773B2 (en) * 2016-08-05 2020-04-14 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
WO2018174544A2 (ko) 2017-03-21 2018-09-27 주식회사 펩트론 Muc1에 특이적으로 결합하는 항체 및 그의 용도
IL269488B2 (en) * 2017-03-21 2023-09-01 Peptron Inc Conjugation of an antibody specifically for muc1 and its use
AU2019235900B2 (en) 2018-03-14 2025-12-11 Dana-Farber Cancer Institute, Inc. Engineered cells, T cell immune modulating antibodies and methods for using the same

Similar Documents

Publication Publication Date Title
JP2022538778A5 (https=)
JP2023534959A5 (https=)
CN306040772S (https=)
CN305667235S (https=)
CN305984614S (https=)
CN305960585S (https=)
CN305959947S (https=)
CN305952140S (https=)
CN305904111S (https=)
CN305902044S (https=)
CN305901230S (https=)
CN305900124S (https=)
CN305896467S (https=)
CN305857584S (https=)
CN305846661S (https=)
CN305830024S (https=)
CN305826653S (https=)
CN305825566S (https=)
CN305824049S (https=)
CN305819511S (https=)
CN305818594S (https=)
CN305536227S (https=)
CN305536172S (https=)
CN305992881S (https=)
CN305818070S (https=)